Is RMD a Buy or a Sell? The Bull and Bear Case (2026)

The most optimistic published target on RMD is $320.00, +38.2% from the $231.52 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.

The most pessimistic published target is $175.00, -24.4% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks ResMed is worth if the risks below bite instead of the drivers above.

Philips is the single largest competitive variable. Its Respironics business exited most of the US new device market after the 2021 foam recall and the subsequent consent decree, handing ResMed several points of share it did not have to compete for. Any credible return of Philips capacity to the US sleep market would meet a ResMed that has been pricing and allocating capital against a diminished rival for five years, and mask share, where switching costs are lowest, would be the first place to show it. The GLP-1 question is genuinely open. ResMed's 2.5 million patient study is observational and self published, and it measures behaviour in the early years of drug adoption rather than the steady state after sustained weight loss; a cohort that loses enough weight to fall below the diagnostic threshold would leave the resupply base entirely. Quality systems are the second live risk. A Class 1 designation on 168,069 Astral units invites FDA scrutiny that can extend past the specific defect into inspection findings, warning letters or a consent decree, and Philips is the cautionary case for how far that can go. Reimbursement adds pressure from the other side: most US revenue passes through home medical equipment suppliers paid by Medicare and commercial plans, so competitive bidding rounds and prior authorisation tightening compress the distributor before they reach ResMed. Manufacturing is concentrated in Singapore, Sydney and Tijuana, which leaves the gross margin exposed to tariffs and freight. Roughly a third of revenue is non-US, so a stronger dollar reduces reported growth. Finally, ~10.9% short interest and a 52 week range of $180.27 to $293.81 mean sentiment, not fundamentals, has been setting the price.

The bear case deserves the same attention as the bull case, and usually gets less. If you are holding RMD already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.

16 analysts cover RMD, with an average target of $245.50 (+6.0% against $231.52) and a split of 7 buy, 11 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the RMD forecast and price target page.

• Revenue (fiscal 2026, trailing twelve months): ~$5.65 billion for fiscal 2026, the twelve months ended June 30, 2026, up ~10% reported and ~8% in constant currency from ~$5.15 billion in fiscal 2025, ~$4.69 billion in fiscal 2024 and ~$4.22 billion in fiscal 2023. Fourth quarter revenue was ~$1.46 billion, a record, up 9% reported and 8% in constant currency, though slightly below the ~$1.47 billion consensus.
• Earnings and margins: GAAP net income of ~$1.52 billion and diluted EPS of $10.43, up ~10%; non-GAAP net income ~$1.63 billion and non-GAAP diluted EPS $11.17, up 17%. GAAP gross margin 61.1% (up 170 basis points) and non-GAAP 62.4% (up 240 basis points). GAAP operating margin 33.4%; non-GAAP 36.1%. Research and development ran ~$378 million and SG&A ~$1.12 billion. Fourth quarter GAAP EPS of $2.64 grew only 2% because of the $42 million Astral provision, while non-GAAP EPS of $2.95 rose 16%.
• Revenue mix (the line a screener misses): Fiscal 2026 devices totalled ~$2.89 billion (~$1.77 billion Americas, ~$1.12 billion rest of world), masks and other consumables ~$2.09 billion (~$1.51 billion Americas, ~$572 million rest of world), and Residential Care Software ~$676 million. Sleep and Breathing Health was ~$4.98 billion of the total. Masks grew 10% in the Americas and 12% internationally in the fourth quarter on a constant currency basis, against ~4% constant currency growth for software across the year.
• Cash flow and balance sheet: Operating cash flow of ~$1.81 billion in fiscal 2026 (up ~3%) and free cash flow of ~$1.65 billion (down ~1%). Cash and equivalents of ~$1.47 billion at June 30, 2026 against ~$659 million of total debt ($260 million short term, $399 million long term), for a net cash position and a debt to equity ratio near 0.13. Assets held for sale of ~$457 million reflect the pending MatrixCare disposal. Return on equity ran ~24% and return on invested capital ~26%.
• Capital returns: ResMed returned more than $1 billion to shareholders in fiscal 2026, roughly 70% more than the prior year: ~$700 million of buybacks and ~$350 million of dividends. The quarterly dividend was raised 10% to $0.66 per share in August 2026, an annualised $2.64 and a yield near 1.1% at ~$232, on a payout ratio around 25% of GAAP earnings. Management guided to more than $1.85 billion of combined buybacks and dividends in fiscal 2027.
• Market pricing: Shares changed hands near $231.52 in late August 2026, inside a 52 week range of $180.27 to $293.81 and down ~20% over twelve months, on ~144.25 million shares outstanding for a ~$33.4 billion market capitalisation and ~$32.8 billion enterprise value. That works out to ~22.2x trailing GAAP EPS, ~20.7x trailing non-GAAP EPS, ~19.2x forward earnings, ~15.6x EV/EBITDA and ~5.8x EV/sales. Beta sits near 0.75 and short interest near 10.9% of shares.

Fiscal 2027 guidance calls for revenue of $5.75 billion to $5.85 billion with core constant currency growth of 5% to 7%, and non-GAAP EPS of $12.00 to $12.25, up 12% to 14%. Both figures absorb the ~$75 million Astral headwind and the MatrixCare divestiture, so the underlying growth rate is higher than the headline. At ~19x that guidance ResMed prices closer to a mature medtech than to the ~30x it commanded before the GLP-1 debate began, which is the whole valuation argument in one number.

Rather than asking whether RMD is a buy in the abstract, it tends to help to answer four questions:

• Thesis: do you believe the bull case above, and is it still true today?
• Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
• Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
• Overlap: check whether you already hold RMD indirectly through an index or sector ETF before adding more.

Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.

• Bull case breaks if: Resupply, not new device placements, carries the growth stalls in the reported numbers rather than in the narrative around them.
• Bear case breaks if: philips is the single largest competitive variable fails to materialise over several reporting periods while the drivers keep compounding.
• Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.

For the full picture, see the RMD stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RMD against your real portfolio and see your actual exposure before deciding.